-
Product Insights
Corneal Ulcers – Drugs In Development, 2023
Global Markets Direct’s, ‘Corneal Ulcers - Drugs In Development, 2023’, provides an overview of the Corneal Ulcers pipeline landscape. The report provides comprehensive information on the therapeutics under development for Corneal Ulcers, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Herpetic Keratitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Herpetic Keratitis - Drugs In Development, 2023’, provides an overview of the Herpetic Keratitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Herpetic Keratitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Viral Keratitis – Drugs In Development, 2023
Global Markets Direct’s, ‘Viral Keratitis - Drugs In Development, 2023’, provides an overview of the Viral Keratitis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Viral Keratitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Persistent Corneal Epithelial Defects – Drugs In Development, 2023
Global Markets Direct’s, ‘Persistent Corneal Epithelial Defects - Drugs In Development, 2023’, provides an overview of the Persistent Corneal Epithelial Defects pipeline landscape. The report provides comprehensive information on the therapeutics under development for Persistent Corneal Epithelial Defects, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Fuchs Endothelial Corneal Dystrophy (FECD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Fuchs Endothelial Corneal Dystrophy (FECD) - Drugs In Development, 2023’, provides an overview of the Fuchs Endothelial Corneal Dystrophy (FECD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fuchs Endothelial Corneal Dystrophy (FECD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Corneal Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Corneal Dystrophy - Drugs In Development, 2023’, provides an overview of the Corneal Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Corneal Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Sicca Syndrome (Sjogren) – Drugs In Development, 2023
Global Markets Direct’s, ‘Sicca Syndrome (Sjogren) - Drugs In Development, 2023’, provides an overview of the Sicca Syndrome (Sjogren) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BSI-060T in Kidney Cancer (Renal Cell Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BSI-060T in Kidney Cancer (Renal Cell Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BSI-060T in Kidney Cancer (Renal Cell Cancer) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Naltrexone Hydrochloride in Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Naltrexone Hydrochloride in Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Naltrexone Hydrochloride in PainDrug Details:ARD-301 is under development for the treatment of fibromyalgia...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TTHX-1114 in Persistent Corneal Epithelial Defects
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TTHX-1114 in Persistent Corneal Epithelial Defects report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TTHX-1114 in Persistent Corneal Epithelial Defects Drug Details: TTHX-1114 is...